YKYurii V. Koshurba

Yurii V. Koshurba

*This is an algorithmically generated author record based on publicly available information.

Yurii V. Koshurba has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cell-free biological agents: new horizons in the treatment of premature newborns (literature review)

    by F.V. Hladkykh, I.V. Koshurba, Ukraine Communal Non-Profit Enterprise Chernivtsi Regional Perinatal Center, M.O. Chyzh, P.S. Zhuchenko, Yu.V. Koshurba

    Preterm birth, is a complex syndrome and remains a major global health problem. Taking into account the plasticity and regenerative potential of developing organs, nowadays the most promising therapeutic strategy is the use of mesenchymal stem cells (MSCs) and their derivatives. Aim. To summarize current information about the therapeutic potential of cell-free biological agents in the treatment of diseases of premature newborns according to data from open sources of information. Publications have been selected, which covered information on the use of conditioned media and MSC exosomes in the treatment of diseases of premature newborns. In comparison to MSCs, the use of cell-free agents has advantages: the use of the secretome eliminates the risks potentially associated with the transplantation of living and proliferative cell populations, including immune compatibility, tumorigenicity, emboli formation, and transmission of infections; MSC-derived secretome can be evaluated for safety, dosage, and efficacy in a manner similar to conventional pharmaceutical agents; storage can be carried out without the use of potentially toxic cryopreservatives for a long period without losing the effectiveness of the product; the use of secretome from MSCs, such as conditioned MSC medium, is more economical and more practical for clinical use, as it avoids invasive cell collection procedures; mass production is possible using custom-made cell lines in controlled laboratory conditions, providing a convenient source of bioactive factors; the time and cost of expansion and maintenance cultured stem cells could be greatly reduced, and ready-made secretome therapies could be immediately available for the treatment of acute conditions; a biological product obtained for therapeutic use can be modified to have the desired cell-specific effects. Conclusions. The treatment of premature newborns represents a unique clinical task, since their diseases involve dynamic physiological processes in immature, developing organs. The introduction into clinical use of cell-free biological agents is one of the most promising areas in the development of neonatology and will obviously change the paradigms in the treatment of a number of diseases of newborns, in particular bronchopulmonary dysplasia, hypoxic ischemic encephalopathy and necrotizing enterocolitis. No conflict of interests was declared by the authors.


  • Open Access

    BRONCHOPULMONARY DYSLASIA OF NEWBORNS AND PROSPECTS OF CELL THERAPY IN UKRAINE AND WORLDWIDE

    by Illia V. Koshurba, Fedir V. Hladkykh, Yurii V. Koshurba

    Introduction. Premature birth is a serious challenge for modern medicine – in the world, about 14.9 million babies are born before 37 weeks of pregnancy, which is approximately 11.0% of all newborns. Bronchopulmonary dysplasia (BLD) is the most common form of chronic lung disease that affects premature babies and contributes to their morbidity and mortality. BPD develops in approximately 25.0% of infants with a birth weight of less than 1,500 g. Among infants born at less than 28 weeks' gestational age, the overall incidence of BPD is estimated to be 48–68%. The limited possibilities of BPD pharmacotherapy prompted the search for new therapeutic approaches. One of the alternatives is biological therapy based on mesenchymal stem cells (MSCs), secretome of MSCs, cryopreserved tissue extracts, etc. The aim of the study: to characterize current information on the therapeutic potential of mesenchymal stem cells in the treatment of newborns with bronchopulmonary dysplasia. Materials and methods. Publications were selected based on the databases PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection, and Google Scholar, which covered information about the pathogenesis of BPD and the prospects for the use of MSCs in the treatment of newborns. Results. Over the past decades, the understanding of the pathogenesis of BPD has evolved from a complication of secondary lung damage after mechanical ventilation and the effect of increased oxygen concentration to a multifactorial disease in which prenatal and postnatal factors are involved. Adult stem cells have been found to be naturally capable of sustaining, generating and replacing terminally differentiated cells. Stem cells function in response to physiological cell turnover or tissue damage due to trauma caused by mechanical ventilation, barotrauma, volutrauma, and hyperoxia in preterm infants. It is believed that the therapeutic effect of MSCs is related to their immunomodulatory, anti-inflammatory, angiogenic, antibacterial and regenerative effects. According to ClinicalTrials.gov, out of 301 clinical studies devoted to BPD, 18 clinical studies are currently known to study the effectiveness of MSCs in the treatment of newborns with BPD, which have already involved 770 newborns. The largest number of studies is conducted in East Asian countries (5 in China, 5 in the Republic of Korea, and 2 in Taiwan). Conclusions. Currently, research into the clinical therapy of BPD with stem cells is mainly focused on umbilical cord blood MSCs, umbilical cord MSCs, and bone marrow MSCs. Success in proving the safety and feasibility of incorporating stem cells for BPD led to the appearance of the biological drug PNEUMOSTEM® – a product of allogeneic MSCs obtained from human umbilical cord blood. Вступ. Передчасні пологи є серйозним викликом для сучасної медицини – у світі близько 14,9 мільйонів дітей народжуються до 37 тижнів вагітності, що становить приблизно 11,0% усіх новонароджених. Найпоширенішою формою хронічного захворювання легень, яке вражає недоношених дітей і сприяє їх захворюваності та смертності виступає бронхолегенева дисплазія (БЛД). БЛД розвивається приблизно у 25,0% немовлят з вагою при народженні менше 1500 г. Серед немовлят, які народилися менше 28 тижнів гестаційного віку, загальна захворюваність на БЛД оцінюється в межах 48–68%. Обмежені можливості фармакотерапії БЛД спонукали до пошуку нових терапевтичних підходів. Однією з альтернатив є біологічна терапія на основі мезенхімальних стовбурових клітин (МСК), секретому МСК, кріоконсервованих екстрактів тканин та ін. Ціль дослідження: охарактеризувати сучасні відомості щодо терапевтичного потенціалу мезенхімальних стовбурових клітин у лікуванні новонароджених з бронхолегеневою дисплазією. Матеріали та методи. Підбір публікацій виконано за базами даних PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection, та Google Scholar, у яких висвітлювались відомості про патогенез БЛД та перспективи застосування МСК у лікуванні новонароджених. Результати. За останні десятиліття уявлення про патогенез БЛД еволюціонувало від ускладнення вторинного ураження легень після механічної вентиляції та дії підвищеної концентрації кисню до мультифакторного захворювання, у якому задіяні пренатальні та постнатальні фактори. Було виявлено, що стовбурові клітини дорослої людини природно здатні підтримувати, генерувати та замінювати кінцево-диференційовані клітини. Стовбурові клітини функціонують у відповідь на фізіологічний обмін клітин або пошкодження тканин внаслідок...

  • Open Access

    GENDER DIFFERENCES IN THE EFFECT OF ANTIULCER DRUGS AND PLACENTA CRYOEXTRACT ON THE INTENSITY OF LIPID PEROXIDATION AND THE ACTIVITY OF THE ANTIOXIDANT SYSTEM IN EXPERIMENTAL HEPATITIS WITH ETHANOL-INDUCED CIRRHOSIS

    by Illia V. Koshurba, Fedir V. Hladkykh, Mykola O. Chyzh, Mykhailo M. Marchenko, Yurii V. Koshurba, Volodymyr B. Hrishyn

    Introduction. It is well recognized that drug metabolism products in the liver can induce oxidative stress and mitochondrial dysfunction, leading to the development of hepatocellular injury. As a potential agent capable of counteracting the hepatotoxic effects of drugs, we focused our attention on a domestic biotechnological preparation – cryopreserved placental extract (CPE). The aim. To characterize gender differences in the effect of esomeprazole, clarithromycin, metronidazole (E/C/M), and CPE on the intensity of lipid peroxidation and the activity of the antioxidant system in tetrachloromethane (CCl4) hepatitis with a background of ethanol-induced cirrhosis (ETCM). Materials and methods. The study was conducted with varying levels of sex hormones on 112 male and female rats. Chronic ETCM was induced by administering a 50.0% oil solution of CCl4 at a dose of 8 ml/kg body weight of the animals twice a week, in combination with a 5.0% ethanol solution for drinking over a period of 45 days. The content of TBA-RP in liver homogenates was determined spectrophotometrically by the method described by Asakawa T. et al. Catalase activity in liver homogenates was determined spectrophotometrically according to the method of Korolyuk M.A. and co-authors. Results. The most pronounced increase in lipid peroxidation processes was observed in females with chronic ETCM-induced liver damage and administration of antiulcer drugs following ovariectomy, resulting in a TBA-RS content of 36.1±2.79 μmol/kg of tissue. Administration of E/C/M in animals with chronic liver damage led to a suppression of the antioxidant system, as evidenced by a decrease in catalase activity in liver tissues. Conclusion. The combined use of anti-ulcer drugs and CPE on the background of chronic ETCM mitigated the activation of lipid peroxidation processes, which was indicated by a statistically significant (p < 0.001) 2.7-fold lower content of TBA-RP in liver homogenates. Additionally, it was established that the administration of CPE was accompanied by a statistically significant increase in catalase activity in females, more prominently than in males. In females without changes in hormonal status, the introduction of CPE resulted in a growth (p < 0.001) of catalase activity by 75.0%, with the most significant increase observed in females after ovariectomy – catalase activity statistically significantly (p < 0.001) increased by 2.6 times compared to the indicators of females not administered with CPE. The administration of CPE in female rats without altering hormonal status was accompanied by a twofold (p < 0.01) increase in the antioxidant-prooxidant index compared to male rats, indicating more pronounced antioxidant properties of CPE in female rats.

  • Open Access

    Anthracycline-induced cardiac injuries and the effect of placenta cryoextract on the myocardium in doxorubicin cardiomyopathy

    by F.V. Hladkykh, M.O. Chyzh, I.V. Koshurba, I.V. Belochkina, Р.р. Коморовський, M.M. Marchenko, Yu.V. Koshurba, І.в. Бєлочкіна

    Background. Doxorubicin is the most widely used drug among anthracyclines. However, despite its clinical effectiveness, the cardiotoxic effect is observed in approximately 25,0% of patients, thus limiting its use. Although significant success in understanding individual pathogenetic elements of the cardiotoxic effect of this drug has been achieved, cancer patients who have doxorubicin-induced cardiac complications are currently treated mostly with drugs for cardiac insufficiency because there is no specific treatment for anthracycline cardiomyopathy. Purpose – to characterize the effect of placenta cryoextract on the course of doxorubicin myocardial injury on the model of chronic doxorubicin cardiomyopathy compared to reference drug vinboron according to the data of biochemical analyses of the heart tissues. Materials and methods. Chronic doxorubicin cardiomyopathy was modeled by the means of injection of doxorubicin hydrochloride at the rate of 5 mg/kg of body weight once a week for 4 weeks (on days 7, 14, 21, 28). The placenta cryoextract was injected on days 1, 7, 14, 21, 28. The animals were withdrawn from the experiment on day 35. The content of adenylic nucleotides, glycogen, pyruvate, lactate, and reactants with thiobarbituric acid was studied in the homogenates of the heart tissues. Results and discussion. The development of doxorubicin cardiomyopathy is accompanied with impaired energy metabolism in the myocardium of animals, as indicated by a statistically significant decrease in the content of adenosine triphosphoric acid (ATP) (p < 0,01) in myocardium tissues by 42,4% and an increase in the content of adenosine diphosphoric acid (ADP) (р < 0,05) and adenosine monosphoric acid (AMP) (p < 0,001) by 45,4% and by 2,2 times respectively relative to the parameters of intact rats. The development of energy disbalance is accompanied with a statistically significant (p< 0,001) increase in the content of reactants with thiobarbituric acid. The use of placenta cryoextract leads to nullifying the energy deficit in myocardium of animals with doxorubicin cardiomyopathy – the level of ATP in the setting of injection of the studied cryoextract increased statistically significantly (p < 0,001) by 72,7%. In addition, in the setting of injection of the studied cryoextract, the «lactate/pyruvate» ratio decreased statistically significantly by 51,9% relative to the parameters of the animals with doxorubicin cardiomyopathy which did not receive treatment and the level of glycogen increased statistically significantly (р < 0,01) by 2 times relative to the parameters of the rats with doxorubicin cardiomyopathy which did not receive treatment, but the content of reactants with thiobarbituric acid decreased (p < 0,05) by 38,9%. Conclusions. Placenta cryoextract shows cardioprotective activity, which is compared to is meant to be used when you’re highlighting similarities, while compared with is supposed to be used when you’re focusing on the differences vinboron, on the model of doxorubicin cardiomyopathy. One of the mechanisms of the mentioned activity is the ability of the studied cryoextract to produce an energystabilizing effect on cardiomyocytes, and also its antioxidative activity.